These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20886212)

  • 1. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
    Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
    Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
    Wei X; Dai G; Liu Z; Cheng H; Xie Z; Klisovic R; Marcucci G; Chan KK
    Drug Metab Dispos; 2008 Nov; 36(11):2227-33. PubMed ID: 18653746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
    Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A
    Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
    Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
    Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTI-2040. Lorus Therapeutics.
    Orr RM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
    Avolio TM; Lee Y; Feng N; Xiong K; Jin H; Wang M; Vassilakos A; Wright J; Young A
    Anticancer Drugs; 2007 Apr; 18(4):377-88. PubMed ID: 17351390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
    Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
    Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered regulation of message stability and tumor promoter-responsive cis-trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells.
    Amara FM; Hurta RA; Huang A; Wright JA
    Cancer Res; 1995 Oct; 55(20):4503-6. PubMed ID: 7553616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
    Fan H; Villegas C; Huang A; Wright JA
    Cancer Res; 1996 Oct; 56(19):4366-9. PubMed ID: 8813126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of antisense oligodeoxynucleotide of small subunit component of human ribonucleotide reductase on human choriocarcinoma cell line in vitro].
    Cui JQ; Shi YF; Zhou HJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):465-8. PubMed ID: 15347470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review).
    Burton TR; Kashour T; Wright JA; Amara FM
    Int J Oncol; 2003 Jan; 22(1):21-31. PubMed ID: 12469181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH; Lim S; Wong WS
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.
    Zhang W; Leighl N; Zawisza D; Moore MJ; Chen EX
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Dec; 829(1-2):45-9. PubMed ID: 16226062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
    Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.
    Cao MY; Lee Y; Feng NP; Xiong K; Jin H; Wang M; Vassilakos A; Viau S; Wright JA; Young AH
    Clin Cancer Res; 2003 Oct; 9(12):4553-61. PubMed ID: 14555530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GTI-2501. Lorus Therapeutics.
    Tu GC; Tu X
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1467-70. PubMed ID: 11890367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.